Peptic Ulcers Market

DelveInsight’s “Peptic Ulcer – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the peptic ulcer, historical and forecasted epidemiology as well as the peptic ulcer market trends in the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan.

 

The peptic ulcer market report provides current treatment practices, emerging drugs, peptic ulcer market share of the individual therapies, and current and forecasted peptic ulcer market size from 2019 to 2032, segmented by seven major markets. The report also covers current peptic ulcer treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

 

Study period: 2019–2032

 

Peptic Ulcer Understanding and Treatment Algorithm

The DelveInsight’s peptic ulcer market report gives a thorough understanding of peptic ulcer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Peptic ulcer disease is a condition in which painful sores or ulcers develop in the lining of the stomach or the first part of the small intestine (the duodenum). Normally, a thick layer of mucus protects the stomach lining from the effect of its digestive juices. But many things can reduce this protective layer, allowing stomach acid to damage the tissue. People of any age who take NSAIDs every day or multiple times per week are more likely to develop a peptic ulcer than people who do not take them regularly. In uncomplicated peptic ulcer disease, the clinical findings are few and nonspecific. Patients with perforated peptic ulcer disease usually present with a sudden onset of severe, sharp abdo. “Alarm features" that warrant prompt gastroenterology referral include bleeding, anemia, early satiety, unexplained weight loss, progressive dysphagia or odynophagia, recurrent vomiting, and a family history of gastrointestinal (GI) conterminal pain. Acute upper gastrointestinal bleeding is a common medical emergency worldwide, a major cause of which are bleeding peptic ulcers.

 

Peptic ulcer diagnosis

Two types of tests are available to diagnose a peptic ulcer. They are called upper endoscopy and upper gastrointestinal (GI) series. Testing for H pylori infection is essential in all patients with peptic ulcers. Rapid urease tests are considered the endoscopic diagnostic test of choice. Of the noninvasive tests, fecal antigen testing is more accurate than antibody testing and is less expensive than urea breath tests but either is reasonable. A fasting serum gastrin level should be obtained in certain cases to screen for Zollinger-Ellison syndrome.

 

Peptic ulcer treatment

Treatment options include empiric antisecretory therapy, empiric triple therapy for H pylori infection, endoscopy followed by appropriate therapy based on findings, and H pylori serology followed by triple therapy for patients who are infected. Breath testing for active H pylori infection may be used.

 

Most patients with peptic ulcer disease are treated successfully with cure of H pylori infection and/or avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs), along with the appropriate use of antisecretory therapy. In the United States, the recommended primary therapy for H pylori infection is proton pump inhibitor (PPI)–based triple therapy. These regimens result in a cure of infection and ulcer healing in approximately 85-90% of cases. Ulcers can recur in the absence of successful H pylori eradication. Endoscopic treatment and acid suppression with proton-pump inhibitors are cornerstones in the management of the peptic ulcer.

 

Peptic Ulcer Epidemiology

The peptic ulcer epidemiology section provides insights into historical and current peptic ulcer patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the peptic ulcer report also provides the diagnosed patient pool, their trends and assumptions undertaken.

 

Key findings

H. pylori causes almost all peptic ulcers, approximately 80 percent of stomach ulcers and more than 90 percent of duodenal ulcers. Duodenal and gastric ulcer disease are closely associated with Helicobacter pylori infection. According to a study conducted by Yutaka et al (2019), the prevalence of gastric and duodenal ulcer has gradually decreased in Japan. The prevalence of Helicobacter pylori infection in Japan has greatly decreased from 49.8% to 31.2% during the 14 years (from 1996 to 2010).

 

The peptic ulcer epidemiology covered in the report provides historical as well as forecasted peptic ulcer epidemiology [segmented as Total Prevalent Cases of Peptic Ulcer, Type specific Cases of Peptic Ulcer, and Total Diagnosed and Treatable Cases of Peptic Ulcer] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Peptic Ulcer Epidemiology

The epidemiology segment also provides the peptic ulcer epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan.

 

Peptic Ulcer Drug Chapters

The drug chapter segment of the peptic ulcer report encloses the detailed analysis of peptic ulcer marketed drugs and late-stage (Phase III and Phase II) peptic ulcer pipeline drugs. It also helps understand the peptic ulcer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging peptic ulcer drugs

The report details the emerging peptic ulcer therapies under the late and mid-stage of development for peptic ulcer treatment.

 

Peptic Ulcer Market Outlook

The peptic ulcer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Peptic ulcer market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the peptic ulcer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the peptic ulcer market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the peptic ulcer market in 7MM.

 

 The United States: Peptic ulcer Market Outlook

This section provides the total peptic ulcer market size and market size by therapies in the United States.

 

 EU4 and the UK: Peptic ulcer Market Outlook

The total peptic ulcer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

 Japan: Peptic ulcer Market Outlook

The total peptic ulcer market size and market size by therapies in Japan is also mentioned.

 

Analyst Commentary

• The pipeline of peptic ulcer is very robust, many potential therapies are being investigated for the treatment of peptic ulcer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the peptic ulcer market in the 7MM. Aside from that, the market size of peptic ulcer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of peptic ulcer may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists

 

Peptic Ulcer Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the peptic ulcer market or expected to get launched in the market during the study period 2019–2032. The analysis covers peptic ulcer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This will help in understanding the peptic ulcer drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Peptic Ulcer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses peptic ulcer’s key players involved in developing targeted therapeutics.

 

 Peptic ulcer market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for peptic ulcer emerging therapies.

 

Peptic Ulcer Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the peptic ulcer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with peptic ulcer market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the peptic ulcer market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• Descriptive overview of peptic ulcer, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the peptic ulcer epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for peptic ulcer, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the peptic ulcer market; historical and forecasted covering drug outreach in the 7MM
• Trends shaping and driving the global peptic ulcer market

 

Report Highlights

• In the coming years, the peptic ulcer market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence peptic ulcer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing peptic ulcer therapies. The launch of emerging therapies will significantly impact the peptic ulcer market
• A better understanding of peptic ulcer pathogenesis will also contribute to the development of novel therapeutics for peptic ulcer
• Our in-depth analysis of the peptic ulcer pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Peptic Ulcer Report Insights

• Patient population
• Therapeutic approaches
• Peptic ulcer pipeline analysis
• Peptic ulcer market size and trends
• Peptic ulcer market opportunities
• Impact of upcoming therapies

 

Peptic Ulcer Report Key Strengths

• 11 years forecast
• 7MM coverage
• Peptic ulcer epidemiology segmentation
• Key cross competition
• KOL views
• Peptic ulcer drugs uptake

 

Peptic Ulcer Report Assessment

• Current treatment practices
• Unmet needs
• Peptic ulcer pipeline product profiles
• Peptic ulcer market attractiveness

 

Key Questions

Peptic ulcer market insights:

• What would be the peptic ulcer market growth till 2032, and what will be the resultant market size in 2032?
• What was the peptic ulcer drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the peptic ulcer total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest peptic ulcer market size during the forecast period (2019–2032)
• How would the unmet needs affect the peptic ulcer market dynamics and subsequent analysis of the associated trends?

 

Peptic ulcer Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of peptic ulcer?
• What is the historical and forecasted peptic ulcer patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and United Kingdom, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Peptic ulcer in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to peptic ulcer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for peptic ulcer and its status, along with the challenges faced?

 

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the peptic ulcer market
• Organize sales and marketing efforts by identifying the best opportunities for peptic ulcer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors